logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

ZTO EXPRESS-W (02057) spent $15.47 million on February 24 to repurchase 617,800 shares.

date
12:30 25/02/2026
avatar
GMT Eight
Zhongtong Express-W (02057) announced on February 24, 2026 that the company will spend 15.47 million US dollars to repurchase 617,800 shares at a repurchase price of 24.67-25.21 US dollars per share.
ZTO EXPRESS-W (02057) announced that on February 24, 2026, the company spent 15.47 million US dollars to repurchase 617,800 shares at a repurchase price of $24.67-25.21 per share.
Related Articles
HK Stock Market Move | ANTENGENE-B(06996) rose more than 6% and reached a clinical cooperation agreement with JUNSHI BIO to advance the joint exploration of ATG-037 and JS207.
CICC: Maintains outperform rating on MEITUAN-W (03690), expects Keeta to implement refined operations in Brazil.
HAITONG INT'L: Maintains a "outperform" rating on CSPC PHARMA (01093), with a target price of HKD 13.07.
HK Stock Market Move | ANTENGENE-B(06996) rose more than 6% and reached a clinical cooperation agreement with JUNSHI BIO to advance the joint exploration of ATG-037 and JS207.
CICC: Maintains outperform rating on MEITUAN-W (03690), expects Keeta to implement refined operations in Brazil.
HAITONG INT'L: Maintains a "outperform" rating on CSPC PHARMA (01093), with a target price of HKD 13.07.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
icon
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
icon
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
icon
07/02/2026
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.